The design of a bispecific antibody constitutes an antitumor scFv targeting a specific malignancy is linked to an anti-CD3/anti-CD16 in order to create an immune connection between cancer cell and the immune effector cells like T cell or NK cell. Here, FCGR3B is linked to cancer.